



Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

April 22, 2024

GAITHERSBURG, Md.--(BUSINESS WIRE)--Apr. 22, 2024-- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that [recently reported](#) twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis will be featured during an oral presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024 in Baltimore, MD. Descartes-08, the Company's lead product candidate, is an autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T).

Details of the presentation are as follows:

- **Abstract Number:** 241
- **Title:** Investigation of mRNA Cell Therapy as a Treatment for Autoimmune Disease in Patients with Myasthenia Gravis
- **Session Title:** Cell Therapy and Cell-Based Gene Therapy Trials
- **Session Date/Time:** Friday May 10, 2024, 1:30-3:15 p.m. E.T.
- **Presentation Time:** 1:45-2:00 p.m. E.T.
- **Room:** Ballroom 1

A copy of the abstract is available through the ASGCT [conference website](#).

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on [LinkedIn](#) or [X](#), formerly known as Twitter.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240422345729/en/): <https://www.businesswire.com/news/home/20240422345729/en/>

Investor Relations:

Melissa Forst
Argot Partners
cartesian@argotpartners.com

Media:

David Rosen
Argot Partners
cartesian@argotpartners.com

Source: Cartesian Therapeutics, Inc.